ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(13)70152-9
◽
2013
◽
Vol 14
(7)
◽
pp. 599-608
◽
Cited By ~ 55
Author(s):
Jie Jin
◽
Jian-Xiang Wang
◽
Fei-Fei Chen
◽
De-Pei Wu
◽
Jiong Hu
◽
...
Keyword(s):
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
De Novo
◽
Open Label
◽
Phase 3
◽
Randomised Controlled
◽
Acute Myeloid
Download Full-text
Related Documents
Cited By
References
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(19)30150-0
◽
2019
◽
Vol 20
(7)
◽
pp. 984-997
◽
Cited By ~ 79
Author(s):
Jorge E Cortes
◽
Samer Khaled
◽
Giovanni Martinelli
◽
Alexander E Perl
◽
Siddhartha Ganguly
◽
...
Keyword(s):
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Salvage Chemotherapy
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
◽
Acute Myeloid
Download Full-text
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
The Lancet
◽
10.1016/s0140-6736(12)60485-1
◽
2012
◽
Vol 379
(9825)
◽
pp. 1508-1516
◽
Cited By ~ 489
Author(s):
Sylvie Castaigne
◽
Cécile Pautas
◽
Christine Terré
◽
Emmanuel Raffoux
◽
Dominique Bordessoule
◽
...
Keyword(s):
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
De Novo
◽
Gemtuzumab Ozogamicin
◽
Adult Patients
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Acute Myeloid
Download Full-text
Faculty Opinions recommendation of Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717952822.793458289
◽
2012
◽
Author(s):
Georg Stüssi
Keyword(s):
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
De Novo
◽
Gemtuzumab Ozogamicin
◽
Adult Patients
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Acute Myeloid
Download Full-text
Faculty Opinions recommendation of Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717958906.793462914
◽
2012
◽
Author(s):
Nelson Chao
Keyword(s):
Complete Remission
◽
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Cell Transplantation
◽
Reduced Intensity Conditioning
◽
Open Label
◽
Phase 3
◽
First Complete Remission
◽
Reduced Intensity
◽
Acute Myeloid
Download Full-text
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
The Lancet Oncology
◽
10.1016/s1470-2045(15)00201-6
◽
2015
◽
Vol 16
(9)
◽
pp. 1025-1036
◽
Cited By ~ 85
Author(s):
Farhad Ravandi
◽
Ellen K Ritchie
◽
Hamid Sayar
◽
Jeffrey E Lancet
◽
Michael D Craig
◽
...
Keyword(s):
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Phase 3
◽
Double Blind
◽
Randomised Controlled
◽
Acute Myeloid
Download Full-text
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30455-1
◽
2020
◽
Vol 21
(9)
◽
pp. 1201-1212
◽
Cited By ~ 5
Author(s):
Li Xuan
◽
Yu Wang
◽
Fen Huang
◽
Zhiping Fan
◽
Yajing Xu
◽
...
Keyword(s):
Stem Cell
◽
Stem Cell Transplantation
◽
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Cell Transplantation
◽
Haematopoietic Stem Cell Transplantation
◽
Haematopoietic Stem Cell
◽
Open Label
◽
Phase 3
◽
Acute Myeloid
Download Full-text
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(15)00200-4
◽
2015
◽
Vol 16
(15)
◽
pp. 1525-1536
◽
Cited By ~ 86
Author(s):
Alessandro Rambaldi
◽
Anna Grassi
◽
Arianna Masciulli
◽
Cristina Boschini
◽
Maria Caterina Micò
◽
...
Keyword(s):
Stem Cell
◽
Stem Cell Transplantation
◽
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Open Label
◽
Phase 3
◽
Haemopoietic Stem Cell
◽
Preparative Regimen
◽
Haemopoietic Stem Cell Transplantation
◽
Acute Myeloid
Download Full-text
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(12)70349-2
◽
2012
◽
Vol 13
(10)
◽
pp. 1035-1044
◽
Cited By ~ 144
Author(s):
Martin Bornhäuser
◽
Joachim Kienast
◽
Rudolf Trenschel
◽
Andreas Burchert
◽
Ute Hegenbart
◽
...
Keyword(s):
Complete Remission
◽
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Cell Transplantation
◽
Reduced Intensity Conditioning
◽
Open Label
◽
Phase 3
◽
First Complete Remission
◽
Reduced Intensity
◽
Acute Myeloid
Download Full-text
Faculty Opinions recommendation of Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717958906.793464270
◽
2012
◽
Author(s):
Anskar YH Leung
Keyword(s):
Complete Remission
◽
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Cell Transplantation
◽
Reduced Intensity Conditioning
◽
Open Label
◽
Phase 3
◽
First Complete Remission
◽
Reduced Intensity
◽
Acute Myeloid
Download Full-text
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
The Lancet Haematology
◽
10.1016/s2352-3026(21)00134-4
◽
2021
◽
Vol 8
(7)
◽
pp. e481-e491
Author(s):
Jeffrey E Lancet
◽
Geoffrey L Uy
◽
Laura F Newell
◽
Tara L Lin
◽
Ellen K Ritchie
◽
...
Keyword(s):
Older Adults
◽
High Risk
◽
Acute Myeloid Leukaemia
◽
Myeloid Leukaemia
◽
Newly Diagnosed
◽
Open Label
◽
Phase 3
◽
Multicentre Phase
◽
Acute Myeloid
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close